- Nachrichtendetail
-
05.07.2024 07:25:04 - dpa-AFX: Genentech's Vabysmo PFS Approved For The Treatment Of Three Leading Causes Of Vision Loss
SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a unit of Roche Holding AG
(RHHBY) Friday said the U.S. Food and Drug Administration or FDA has approved
its Vabysmo prefilled syringe (PFS) to treat age-related macular degeneration
(AMD) diabetic macular edema (DME) and macular edema following retinal vein
occlusion (RVO).
Vabysmo PFS, which delivers the same medicine as the currently available Vabysmo
vials, will be available in the coming months, the company said in a statement.
Vabysmo is currently approved in more than 95 countries for wet AMD and DME, and
in several countries, including the U.S. and Japan, for RVO.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
(RHHBY) Friday said the U.S. Food and Drug Administration or FDA has approved
its Vabysmo prefilled syringe (PFS) to treat age-related macular degeneration
(AMD) diabetic macular edema (DME) and macular edema following retinal vein
occlusion (RVO).
Vabysmo PFS, which delivers the same medicine as the currently available Vabysmo
vials, will be available in the coming months, the company said in a statement.
Vabysmo is currently approved in more than 95 countries for wet AMD and DME, and
in several countries, including the U.S. and Japan, for RVO.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ROCHE HLDG AG GEN. | 855167 | Hamburg | 0,000 | 08.07.24 21:37:11 | ±0,000 | ±0,00% | 0,000 | 0,000 | 0,000 | 245,550 |
